Rakez Kayed
#155,037
Most Influential Person Now
Researcher
Rakez Kayed's AcademicInfluence.com Rankings
Rakez Kayedcomputer-science Degrees
Computer Science
#8468
World Rank
#8901
Historical Rank
Machine Learning
#3474
World Rank
#3517
Historical Rank
Artificial Intelligence
#3775
World Rank
#3830
Historical Rank
Database
#5473
World Rank
#5678
Historical Rank
Download Badge
Computer Science
Rakez Kayed's Degrees
- PhD Computer Science University of California, Berkeley
- Masters Computer Science Stanford University
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Rakez Kayed Influential?
(Suggest an Edit or Addition)Rakez Kayed's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis (2003) (3868)
- Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction (2003) (3694)
- A specific amyloid-β protein assembly in the brain impairs memory (2006) (2572)
- Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* (2005) (2042)
- A specific amyloid-beta protein assembly in the brain impairs memory. (2006) (1267)
- Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ (2005) (979)
- Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* (2004) (856)
- Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers (2007) (709)
- Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* (2007) (678)
- iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases (2017) (599)
- NLRP3 inflammasome activation drives tau pathology (2019) (579)
- The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy (2016) (468)
- Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice (2011) (437)
- Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* (2012) (424)
- Identification of oligomers at early stages of tau aggregation in Alzheimer's disease (2012) (409)
- Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau (2012) (398)
- Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis (2006) (371)
- Structural and Dynamic Features of Alzheimer's Aβ Peptide in Amyloid Fibrils Studied by Site-directed Spin Labeling* (2002) (345)
- Molecular mechanisms of amyloid oligomers toxicity. (2012) (340)
- Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer* (2009) (334)
- Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. (1999) (324)
- Preparation and characterization of neurotoxic tau oligomers. (2010) (310)
- Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. (2004) (277)
- Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. (2021) (236)
- Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. (2013) (232)
- Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles (2014) (227)
- Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. (2007) (218)
- Soluble Amyloid Oligomers Increase Bilayer Conductance by Altering Dielectric Structure (2006) (217)
- Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. (2006) (192)
- Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP–Induced β-Cell Apoptosis in h-IAPP Transgenic Mice (2007) (168)
- Loss of α7 Nicotinic Receptors Enhances β-Amyloid Oligomer Accumulation, Exacerbating Early-Stage Cognitive Decline and Septohippocampal Pathology in a Mouse Model of Alzheimer's Disease (2010) (168)
- Conformation-dependent anti-amyloid oligomer antibodies. (2006) (167)
- ERK1/2 Activation Mediates Aβ Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures* (2006) (164)
- Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. (2006) (161)
- Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers (2010) (146)
- Soluble and mature amyloid fibrils in drusen deposits. (2010) (141)
- Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. (2014) (133)
- Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies (2015) (129)
- Amyloid-β Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain*♦ (2011) (124)
- Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury (2013) (122)
- Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model (2015) (119)
- Age-dependent axonal degeneration in an Alzheimer mouse model (2007) (118)
- Aβ Amyloid Pathology Affects the Hearts of Patients With Alzheimer's Disease: Mind the Heart. (2016) (114)
- Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases (2016) (108)
- Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. (2005) (108)
- Isolation, structural, and functional characterization of an apoptosis-inducing L-amino acid oxidase from leaf-nosed viper (Eristocophis macmahoni) snake venom. (2000) (105)
- Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain (2005) (104)
- Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate (2009) (102)
- Formation and Propagation of Tau Oligomeric Seeds (2013) (100)
- α‐Synuclein oligomers oppose long‐term potentiation and impair memory through a calcineurin‐dependent mechanism: relevance to human synucleopathic diseases (2012) (97)
- Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. (2014) (97)
- Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice (2010) (91)
- Selective induction of calcineurin activity and signaling by oligomeric amyloid beta (2008) (87)
- Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons (2020) (87)
- TDP-43 Phosphorylation by casein kinase Iε promotes oligomerization and enhances toxicity in vivo. (2014) (78)
- Pore-Forming Proteins Share Structural and Functional Homology with Amyloid Oligomers (2007) (77)
- Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective (2020) (76)
- Characterization of tau oligomeric seeds in progressive supranuclear palsy (2014) (74)
- Exercise reverses preamyloid oligomer and prolongs survival in αB-crystallin-based desmin-related cardiomyopathy (2007) (73)
- Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. (2016) (70)
- Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross‐seeding behavior (2018) (69)
- Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. (2013) (69)
- Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. (2010) (68)
- Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo (2015) (65)
- Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies (2017) (65)
- The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes (2014) (60)
- Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. (2014) (59)
- Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. (2009) (58)
- Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin (2008) (57)
- Advances and considerations in AD tau-targeted immunotherapy (2019) (57)
- α-Synuclein Oligomers Induce a Unique Toxic Tau Strain (2018) (57)
- The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration (2015) (54)
- P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease (2020) (54)
- Tau oligomers in cerebrospinal fluid in Alzheimer's disease (2017) (52)
- LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein Published, JLR Papers in Press, October 16, 2004. DOI 10.1194/jlr.M400306-JLR200 (2005) (51)
- Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy (2018) (51)
- Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model (2016) (49)
- Potential mechanisms and implications for the formation of tau oligomeric strains (2016) (47)
- Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies (2020) (45)
- Inhaled insulin forms toxic pulmonary amyloid aggregates. (2010) (45)
- Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease (2014) (45)
- Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. (2005) (44)
- Tau Interacts with the C-Terminal Region of α-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations. (2019) (43)
- Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits (2017) (42)
- A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain (2009) (42)
- Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies (2012) (42)
- Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia. (2020) (40)
- Astrocytes contain amyloid‐β annular protofibrils in Alzheimer's disease brains (2011) (39)
- Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease (2010) (39)
- Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies (2018) (39)
- Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice (2012) (38)
- TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia (2020) (38)
- RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction (2020) (37)
- A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1 (2015) (35)
- Tau aggregates as immunotherapeutic targets. (2013) (33)
- Critical Role of the CXCL10/C-X-C Chemokine Receptor 3 Axis in Promoting Leukocyte Recruitment and Neuronal Injury during Traumatic Optic Neuropathy Induced by Optic Nerve Crush. (2017) (33)
- Novel Aβ peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease (2005) (32)
- Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives (2019) (32)
- Purification and primary structure of low molecular mass peptides from scorpion (Buthus sindicus) venom. (1998) (30)
- Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification (2009) (29)
- Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits (2018) (27)
- Azure C Targets and Modulates Toxic Tau Oligomers. (2018) (27)
- Poloxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. (2009) (27)
- Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. (2017) (26)
- Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk (2020) (25)
- CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease (2008) (25)
- Tau oligomers mediate aggregation of RNA‐binding proteins Musashi1 and Musashi2 inducing Lamin alteration (2019) (24)
- Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration. (2010) (24)
- ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function (2011) (23)
- Rational design, conformational studies and bioactivity of highly potent conformationally constrained calcitonin analogues. (1999) (23)
- Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis (2012) (22)
- Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases (2022) (21)
- Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury (2019) (21)
- Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. (2017) (20)
- Modulating disease-relevant tau oligomeric strains by small molecules (2020) (20)
- Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer’s disease (2018) (20)
- Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies (2018) (20)
- Immunization with fibrillar Aβ1–42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ (2006) (20)
- Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein (2020) (18)
- Therapeutic Approaches Targeting Pathological Tau Aggregates. (2016) (17)
- The influence of the carboxyl terminus of the Alzheimer Aβ peptide on its conformation, aggregation, and neurotoxic properties (2002) (17)
- Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain (2005) (17)
- Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides. (2018) (17)
- Antibody against Small Aggregated Peptide Specifically Recognizes Toxic Aβ-42 Oligomers in Alzheimer's Disease. (2015) (17)
- Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer’s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers (2020) (17)
- Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis (2011) (16)
- Design of metastable β-sheet oligomers from natively unstructured peptide. (2013) (15)
- O2-05-05 IVIg contains antibodies against oligomers and fibrils of beta amyloid (2007) (14)
- AAV2-mediated GRP78 Transfer Alleviates Retinal Neuronal Injury by Downregulating ER Stress and Tau Oligomer Formation (2018) (14)
- Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes (2015) (14)
- Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target? (2013) (13)
- Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins (2011) (12)
- Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. (2011) (11)
- Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra‐lesional injections of anti‐amyloid antibodies (2010) (11)
- Preparation and Characterization of Tau Oligomer Strains. (2018) (11)
- Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity (2016) (10)
- Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes (2021) (10)
- Early alterations of neurovascular unit in the retina in mouse models of tauopathy (2021) (10)
- Tau Protein: Function and Pathology (2012) (9)
- Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. (2006) (9)
- Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers (2021) (8)
- Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe. (2013) (7)
- β-Amyloid (Aβ) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation (2005) (7)
- Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease (2022) (7)
- Toxic Human IAPP Oligomers are Intracellular , and Vaccination to Induce Anti-toxic Oligomer Antibodies Does not Prevent Human IAPP Induced Beta-Cell Apoptosis in Human IAPP Transgenic Mice (2007) (7)
- Evidence for distinct actions of oligomers and fibrils of hIAPP (2006) (6)
- Oligomer Formation and Cross‐Seeding: The New Frontier (2017) (6)
- Theory of concentric β-barrel structures: models of amyloid beta 42 oligomers, annular protofibrils, and transmembrane channels (2018) (5)
- Curcumin as Scaffold for Drug Discovery against Neurodegenerative Diseases (2021) (5)
- Tau induces formation of α-synuclein filaments with distinct molecular conformations. (2021) (5)
- Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease (2021) (4)
- Post-translational Modifications of the p53 Protein and the Impact in Alzheimer’s Disease: A Review of the Literature (2021) (4)
- Oxygen transport proteins: III. Structural studies of the scorpion (Buthus sindicus) hemocyanin, partial primary structure of its subunit Bsin1. (2000) (4)
- Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding (2021) (4)
- O4-02-02 Common structure and mechanism of soluble amyloid oligomer pathogenesis in degenerative diseases (2004) (4)
- The amyloid concentric β-barrel hypothesis: Models of amyloid beta 42 oligomers and annular protofibrils (2021) (4)
- New vaccine development for chronic brain disease (2010) (4)
- Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. (2005) (4)
- Distinct neurotoxic TDP-43 fibril polymorphs are generated by heterotypic interactions with α-Synuclein (2022) (4)
- Infectious etiology and amyloidosis in Alzheimer's disease: The puzzle continues (2021) (3)
- Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies (2022) (3)
- Amyloid β -Peptide and Oligomers in the Brain and CSF of Aged Canines (2010) (3)
- TRIM28 regulates the stability and toxicity of alpha-synuclein and tau through a common mechanism (2015) (3)
- The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity (2017) (3)
- Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC-induced neurons with the V337M MAPT mutation (2021) (3)
- Elucidating the pathogenic mechanisms of AD brain‐derived, tau‐containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons (2020) (2)
- Characterization of tau oligomeric seeds in progressive supranuclear palsy (2014) (2)
- Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: from discovery to therapy. (2023) (2)
- Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease (2020) (2)
- Tau Oligomers in Traumatic Brain Injury 1 Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury : Possible Link Between TBI and Sporadic Tauopathies (2013) (2)
- TAU-INDUCED ASTROCYTE SENESCENCE: A NOVEL MECHANISM FOR NEURONAL DYSFUNCTION IN ALZHEIMER’S DISEASE (2019) (2)
- TAU OLIGOMERS DERIVED FROM TRAUMATIC BRAIN INJURY CAUSE TOXICITY AND COGNITIVE IMPAIRMENT IN HTAU MICE (2014) (1)
- Similarities between AMD and amyloid diseases suggested by the presence of toxic, amyloidogenic oligomers in drusen (2004) (1)
- Brain Derived Biologically Relevant Tau Oligomers (2022) (1)
- EXOSOMES CONTAINING SPECIFIC TAU OLIGOMER FORMATIONS ACCELERATE PATHOLOGICAL TAU PHOSPHORYLATION IN C57BL/6 MICE (2018) (1)
- P1-172 Annular protofibrils, formation, stability and toxicity: new insights into the pore-like mechanism for amyloid toxicity (2004) (1)
- The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes (2014) (1)
- Amyloid oligomer interactions and polymorphisms: disease-relevant distinct assembly of α-synuclein and tau (2018) (1)
- TAU AND P53 IN ALZHEIMER’S DISEASE (2017) (1)
- Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner. (2022) (1)
- Reduction of tau oligomers by immunotherapy improves cognition in an Alzheimer’s disease mouse model (2013) (1)
- Multiple Effects of Soluble Amyloid Peptide Oligomers on Human Potassium Channels (2007) (1)
- Amyloid Hypothesis: Molecular and Cellular Aspects of Toxicity (2012) (1)
- Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment (2011) (1)
- Quantification and targeting of elusive neurotoxic amyloid oligomers (2022) (1)
- Untwisted α-synuclein Filaments formed in the Presence of Lipid Vesicles (2021) (1)
- Tau oligomers trigger inflammation in the eyes of the Alzhiemer’s disease mouse models (2015) (1)
- Formation of toxic oligomeric species from different proteins in Alzheimer's disease: Potential toxic interactions at the oligomer aggregation stage (2013) (1)
- OLIGOMERS OF A-SYNUCLEIN CROSS-SEED TAU AND EXTEND LIFETIME OF TAU TOXIC CONFORMATION (2014) (1)
- P1-054 AN EXPLORATION OFA FUNCTIONAL UNIT OF DNA METHYLATION IN THE AGING BRAIN (2013) (0)
- DIFFERENT OLIGOMERIC TAU STRAINS ARE DETECTED WITH NOVEL ANTI-TAU OLIGOMER-SPECIFIC ANTIBODIES (2014) (0)
- TAU OLIGOMERS MEDIATE AGGREGATION OF RNA-BINDING PROTEINS MUSASHI1- AND MUSASHI2-INDUCING NUCLEAR MEMBRANE ALTERATION IN ALZHEIMER’S DISEASE (2019) (0)
- Immunotherapy Targeting Tau Oligomeric Strains in Aged Transgenic Animals of Tauopathy (2018) (0)
- INVESTIGATING THE POTENTIAL OF NOVEL CURCUMIN DERIVATIVES IN TARGETING AND MODULATING TOXIC TAU OLIGOMERIC STRAINS (2017) (0)
- Advances in tau immunotherapy (2016) (0)
- Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology (2020) (0)
- P1-028 Axonopathy in APP/PS1 transgenic mouse models of Alzheimer’s disease (2006) (0)
- Erratum: (Journal of General Physiology (2006) 128, 6 (637-647)) (2006) (0)
- Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy (2018) (0)
- TAU IMMUNOTHERAPY FOR ALPHA-SYNUCLEINOPATHY (2018) (0)
- NLRP3 inflammasome activation drives tau pathology (2019) (0)
- Tau oligomers and annular protofibrils in progressive supranuclear palsy (2013) (0)
- Amyloid fibril formation by partially unfolded islet amyloid polypeptide (IAPP) (2002) (0)
- Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC‐induced neurons with the V337M MAPT mutation (2021) (0)
- Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein (2020) (0)
- Corrigendum: Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity (2017) (0)
- Induction of calcineurin activity and signaling by oligomeric amyloid-beta isolated from Alzheimer brains (2009) (0)
- The Hsp90 co-chaperone FKBP51 produces neurotoxic tau oligomers: Implication for aging and Alzheimer's disease (2013) (0)
- Specific targeting of tau oligomeric seeds by passive immunization (2013) (0)
- Specific clearance of tau oligomers by passive immunization (2012) (0)
- TAU OLIGOMERIC STRAINS IN SYNUCLEINOPATHIES (2017) (0)
- Differential dynamics of Aβ and tau oligomer synaptic binding may suggest diverse therapeutic targets for early vs. late Alzheimer's disease (2020) (0)
- A Novel Therapeutic Approach to Polyomavirus-Associated Diseases (2014) (0)
- Evaluating Passive Immunotherapy using Aged Transgenic Animals of Tauopathy (2018) (0)
- Transported in Neurons Anterogradely and Retrogradely Internalized via Bulk Endocytosis and Small Misfolded Tau Species Are Molecular Bases of Disease (2013) (0)
- EVALUATING TAU OLIGOMERS PASSIVE IMMUNOTHERAPY USING AGED TRANSGENIC ANIMALS OF TAUOPATHY (2017) (0)
- Onset of Insulin Resistance in Hippocampal Synapses After Traumatic Brain Injury : Relevance to Alzheimer ’ s disease and Therapeutic Implications (2019) (0)
- iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death (2021) (0)
- HMGB1‐Mediated Senescence and Brain Inflammation Contributes to Cognitive Dysfunctions (2022) (0)
- POLYMORPHISM AND TOXIC INTERACTIONS BETWEEN SOLUBLE AMYLOID OLIGOMERS AND TAU (2019) (0)
- AD‐ and PSP‐specific brain‐derived tau oligomers engage synapses with different dynamic (2021) (0)
- Immunogens and corresponding antibodies, which are specific for frequent high molecular weight aggregation intermediates of amyloid proteins from different sequence (2003) (0)
- Functional spreading of hyperexcitability induced by human and synthetic intracellular Aβ oligomers (2020) (0)
- P2-291: Administration of CNI-1493 inhibits Aβ accumulation, Amyloid plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease (2008) (0)
- TDP-43 HYBRID OLIGOMERS IN ALZHEIMER'S DISEASE (2014) (0)
- Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies (2012) (0)
- POLYMORPHISM AND TOXIC INTERACTIONS BETWEEN SOLUBLE AMYLOID OLIGOMERS AND TAU (2019) (0)
- Targeted Musashi1 knockdown leads to reduce tau pathology and improves cognitive function in aged P301L mouse model (2022) (0)
- Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies (2023) (0)
- INHIBITION OF PHOSPHOLIPASE D1 AS A THERAPEUTIC IN AD-RELATED MEMORY DEFICITS (2018) (0)
- P4-264: Oligomers from different disease-related amyloid proteins induce common neurodysfunctional events (2008) (0)
- Longitudinal characterization of retinal vasculature alterations with optical coherence tomography angiography in a mouse model of tauopathy (2022) (0)
- TAU OLIGOMER-SPECIFIC ANTIBODIES IN INTRAVENOUS IMMUNOGLOBULINS (IVIGS): POTENTIAL THERAPEUTIC SIGNIFICANCE IN ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE TAUOPATHIES (2014) (0)
- Early alterations of neurovascular unit in the retina in mouse models of tauopathy (2021) (0)
- Tau modulates mRNA transcription, alternative polyadenylation (APA) profiles of hnRNPs, chromatin remodeling and spliceosome complexes (2022) (0)
- O2-04-06 New lessons form the APP/PS1 transgenic mouse model with neuron loss: Metal biology, axonal degeneration and intraneuronal N-modified Aβ aggregation (2006) (0)
- Tau Immunotherapy for Alpha-Synucleinopathy (2018) (0)
- Author response: A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1 (2015) (0)
- Author response: Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes (2015) (0)
- Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies (2018) (0)
- P3-430 Conformation-dependent antibodies reveal the complexity of amyloid formation via seeding and cross-seeding (2006) (0)
- Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies (2020) (0)
- P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease (2020) (0)
- TAU-MEDIATED CELL DEATH MECHANISMS IN MAPT V337M IPSC-DERIVED HUMAN NEURONS (2019) (0)
- Association of pathological tau with the ribosomal complex impairs protein synthesis (2015) (0)
- Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice (2012) (0)
- Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer’s disease (2018) (0)
- AAV2-GRP78-mediated gene therapy prevents retinal neuronal injury via downregulation of Tau oligomers (2017) (0)
- TOXICITY AND PROPAGATION OF TBI BRAIN-DERIVED SOLUBLE TAU STRAINS (2018) (0)
- The synaptic interplay of Tau and Aβ oligomeric species in Alzheimer’s disease and related tauopathies. (2022) (0)
- Tau oligomer antibodies as potential therapeutics for parkinson’s and other synucleinopathies (2015) (0)
- Novel super-potent conformationally constrained calcitonin (ct) analogues (1997) (0)
- SELECTED MICRO RNAS FROM NEURAL STEM CELL–DERIVED EXOSOMES INCREASE SYNAPTIC RESILIENCE TO TAU AND Aβ OLIGOMERS (2018) (0)
- Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies (2018) (0)
- A Complex Containing HNRNPA2B1 and N6-methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers (2020) (0)
- PROPAGATION OF SOLUBLE TAU AGGREGATES IN BRAIN MICROVASCULAR ENDOTHELIAL CELLS PROMOTES CELLULAR SENESCENCE/SASP AND BLOCKS ENOS ACTIVATION (2019) (0)
- P1-100 CNI-1493 inhibits Aβ production and prevents plaque formation in an animal model of Alzheimer’s disease (2006) (0)
- Tau oligomers in CSF: A novel biomarker for the diagnosis and evaluation of treatment for Alzheimer's disease and tauopathies (2013) (0)
- Alzheimer’s disease brain-derived tau-containing extracellular vesicles: Pathobiology and GABAergic neuronal transmission (2020) (0)
- Distinct cryo-EM Structure of α-synuclein Filaments derived by Tau (2021) (0)
- PATHOLOGICAL TAU SPECIES ABROGATE NASCENT PROTEIN PRODUCTION BY ASSOCIATING WITH THE RIBOSOMAL COMPLEX: IMPLICATIONS OF A NOVEL TAU FUNCTION AND ITS PATHOGENIC LINK TO MEMORY IMPAIRMENT (2014) (0)
- PROPAGATION AND DIVERSE EFFECTS OF DISEASE-SPECIFIC PRION-LIKE TAU OLIGOMERIC STRAINS (2018) (0)
- Effect of immunization with the oligomeric form of the Aβ peptide: Reduction of senile plaque area, decreased complement C3 deposition and synthesis, and decline in behavioral function in a murine model of Alzheimer's disease (2007) (0)
- Compositions et methodes d'inhibition de la formation de drusen et methodes de diagnostic ou de traitement de pathologies liees aux drusen (2006) (0)
- INCREASED SYNAPTIC SENSITIVITY TO Aβ AND TAU OLIGOMERS IN THE AGING CNS AS A FUNCTION OF DECREASING NEURAL STEM CELLS (2018) (0)
- A Complex Containing HNRNPA2B1 and N 6-Methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers (2020) (0)
- Review for "Maintained memory and long‐term potentiation in a mouse model of Alzheimer’s disease with both amyloid pathology and human tau" (2020) (0)
- Alpha-synuclein oligomers induce calcineurin-dependent neurotoxicity and memory deficits (2009) (0)
- Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy (2023) (0)
- TBI AND AD: SIMILAR TAU-INDUCED NEURODEGENERATION? (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rakez Kayed?
Rakez Kayed is affiliated with the following schools:
